Investigation of intrinsic dissolution behavior of different carbamazepine samples

International Journal of Pharmaceutics

Volumn 386, Issue 1-2, 2010, Pages 77-90

  Šehić, Selma ^a,b   Betz, Gabriele ^a   Hadžidedić, Šeherzada ^b   El Arini, Silvia Kocova ^c   Leuenberger, Hans ^a,d  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Bosnalijek dd   (Bosnia and Herzegovina)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d Ifiip   (Switzerland)

Author keywords

Carbamazepine; Dihydrate; Intrinsic dissolution; Phase transformation; Polymorphism

Indexed keywords

CARBAMAZEPINE; LACTOSE; LUDIPRESS; MAGNESIUM STEARATE; POVIDONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG QUALITY; DRUG SOLUBILITY; PARTICLE SIZE; PRIORITY JOURNAL; TABLET COMPRESSION;

ANTICONVULSANTS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; EXCIPIENTS; KINETICS; MICROSCOPY, ELECTRON, SCANNING; MICROSPECTROPHOTOMETRY; PARTICLE SIZE; POWDER DIFFRACTION; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TABLETS; TECHNOLOGY, PHARMACEUTICAL; THERMOGRAVIMETRY;

EID: 74249085196     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.10.051     Document Type: Article

References (31)

1. Bolourtchian N., Nokhodochi A., and Dinarvand R. The effect of solvent and crystallization conditions on habit modification of carbamazepine. Daru 9 (2001) 12-22
2. Brittain H.G. Methods for characterization of polymorphs and solvates. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids vol. 95 (1999), Marcel Dekker Inc., New York, Basel 228-280
3. Carino S.R., Sperry D.C., and Hawley M. Relative bioavailability estimation of carbamazepine crystal forms using an artificial Stomach-Duodenum model. J. Pharm. Sci. 95 (2006) 116-125
4. Grzesiak A.L., Lang M., Kim K., and Matzger A.J. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J. Pharm. Sci. 92 (2003) 2260-2271
5. Hanson R., and Gray V. Dissolution testing of solid dosage forms. In: Hanson R., and Gray V. (Eds). Handbook of Dissolution Testing. 3rd ed. (2004), Dissolution Technologies, Inc., Hockessin, Delaware 33-71
6. Kaneniwa K., Yamagouchi T., Watari N., and Otsuka M. Hygroscopicity of carbamazepine crystalline powder. Yakugaku Zasshi 104 (1984) 184-190
7. Kaneniwa N., Ichikawa J., Yamaguchi T., Hayashi K., Watari N., and Sumi M. Dissolution behavior of carbamazepine polymorphs. Yakugaku Zasshi 107 (1987) 808-813
8. Kobayashi Y., Ito S., Itai S., and Yamamoto K. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 193 (2000) 137-146
9. Krahn F.U., and Mielck J.B. Effect of type and extent of crystalline order on chemical and physical stability of carbamazepine. Int. J. Pharm. 53 (1989) 25-34
10. Krahn F.U., and Mielck J.B. Relation between several polymorphic forms and the dihydrate of carbamazepine. Pharma. Acta Helv. 62 (1987) 247-254
11. Li Y., Han J., Zhang G.G.Z., Grant D.J.W., and Suryanarayanan R. In situ dehydration of carbamazepine dihydrate: a novel technique to prepare amorphous anhydrous carbamazepine. Pharm. Dev. Technol. 5 (2000) 257-266
12. McMahon L.E., Timmins P., Williams A.C., and York P. Characterization of dihydrates prepared from carbamazepine polymorphs. J. Pharm. Sci. 85 (1996) 1064-1069
13. Meyer M.C., Straughn A.B., Jarvi E.J., Wood G.C., Pelsor F.R., and Shah V.P. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm. Res. 9 (1992) 1612-1616
14. Meyer M.C., Straughn A.B., Mhatre R.M., Shah V.P., Williams R.L., and Lesko L.J. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm. Res. 15 (1998) 1787-1791
15. Murphy D., Rodriguez-Cintron F., Langevin B., Kelly R.C., and Rodrriguez-Hornedo N. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. Int. J. Pharm. 246 (2002) 121-134
16. Nogami H., Nagai T., and Yotsuyamnagi T. Dissolution phenomena of organic medicinals involving simultaneous phase changes. Chem. Pharm. Bull. 17 (1969) 499-509
17. Nokhodochi A., Bolourtchian N., and Dinarvand R. Dissolution and mechanical behaviors of recrystallized carbamazepine from alcohol solution in the presence of additives. J. Cryst. Growth 274 (2004) 573-584
18. Ono M., Tozuka Y., Oguchi T., Yamamura S., and Yamamoto K. Effects of dehydration temperature on water vapor adsorption and dissolution behavior of carbamazepine. Int. J. Pharm. 239 (2002) 1-12
19. Otsuka M., Hasegawa H., and Matsuda Y. Effect of polymorphic forms of bulk powders on pharmaceutical properties of carbamazepine granules. Chem. Pharm. Bull. 47 (1999) 852-856
20. Otsuka M., Hasegawa H., and Matsuda Y. Effect of polymorphic transformation during the extrusion-granulation process on the pharmaceutical properties of carbamazepine granules. Chem. Pharm. Bull. 45 (1997) 894-898
21. Qu H., Louhi-Kultanen M., and Kallas J. Solubility and stability of anhydrate/hydrate in solvent mixtures. Int. J. Pharm. 321 (2006) 101-107
22. Rodriguez-Hornedo N., and Murphy D. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. J. Pharm. Sci. 93 (2004) 449-460
23. Rustichelli C., Gamberini G., Ferioli V., Gamberini M.C., Ficarra R., and Tommasini S. Solid-state study of polymorphic drugs: carbamazepine. J. Pharm. Biomed. Anal. 23 (2000) 41-54
24. Sehic, S., 2008. Investigation of variability of primary materials on the intrinsic dissolution behavior of carbamazepine. PhD Thesis, University of Basel, Switzerland.
25. Sethia S., and Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int. J. Pharm. 272 (2004) 1-10
26. Shefter E., and Higuchi T. Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals. J. Pharm. Sci. 52 (1963) 781-791
27. Surana R., Pyne A., and Suryanarayanan R. Solid-vapor interactions: influence of environmental conditions on the dehydration of carbamazepine dihydrate. AAPS Pharm. Sci. Tech. 4 (2003) 1-10
28. Umeda T., Ohnishi N., Yokoyama T., Kuroda K., Kuroda T., and Matsuda Y. Kinetics of the thermal transition of carbamazepine polymorphic forms in the solid state. Yakugaku Zasshi 104 (1984) 786-792
29. US Pharmacopoeia 31, 2008. Carbamazepine immediate release tablets. The United States Pharmacopoeial Convention, Rockville, MD, pp. 1631-1632.
30. Wang J.T., Shiu G.K., Ong-Chen T., Vitswanathan C.T., and Skelly J.P. Effects of humidity and temperature on in vitro dissolution of carbamazepine tablets. J. Pharm. Sci. 83 (1993) 1002-1005
31. Yu L.X., Carlin A.S., Amidon G.L., and Hussain A.S. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. International Journal of Pharmaceutics 270 1-2 (2004) 221-227